HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

Cancer

Volumn 94, Issue 8, 2002, Pages 2169-2173

  Vincent Salomon, Anne ^a   Jouve, Michel ^a   Genin, Pascal ^a   Fréneaux, Paul ^a   Sigal Zafrani, Brigitte ^a   Caly, Martial ^a   Beuzeboc, Philippe ^a   Pouillart, Pierre ^a   Sastre Garau, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast carcinoma; HER2; Immunotherapy; Metastases; Preoperative chemotherapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P185;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MITOSIS; ONCOGENE NEU; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 0037089578     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10456     Document Type: Article

References (20)

1. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
2. Prognostic importance of c-erbB-2 expression in breast cancer
3. HER-2/neu in nodenegative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
4. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of ERBB2 (HER-2/neu) gene status in breast carcinoma
5. Inflammatory breast carcinoma: An immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR
6. Genetic alterations in early-onset invasive breast carcinomas: Correlations of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype
7. ERBB2 overexpression in breast carcinomas: No positive correlation with complete pathological response to preoperative high-dose-anthracycline-based chemotherapy
8. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
9. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma
10. Assessment of Her2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study
11. Stability of HER-2/neu expression over time and at multiple metastatic sites
12. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
13. Comparison of fluorescence in situ hybridization and immunohistochemistry for evaluation of HER-2/neu in breast cancer
14. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
15. Predictive value of c-erbB-2, p53, cathepsin-D and histological of the primary tumour in metastatic breast cancer
16. HER-2/neu/ErbB-2 status by immunohistochemistry and FISH: Clonality and progression with recurrence and metastases
17. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
18. c-erbB-2 expression in benign and malignant breast disease
19. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases
20. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer